Johnson & Johnson has made a commitment of up to $200 million to speed up the development of an Ebola vaccine at its Janssen Pharmaceutical Companies.
The company is closely collaborating with the World Health Organization, the National Institute of Allergy and Infectious Diseases and other public health authorities and organizations.
"We are urgently working to provide our vaccine expertise, production capabilities, our people and resources to address the Ebola crisis," Johnson & Johnson Chairman and CEO Alex Gorsky said. "Our innovation model enables us to quickly mobilize our extensive resources to collaborate with health authorities and governments and other experts to help contain this disease, save lives, and protect the health and lives of those at risk. We have an important responsibility as a leading global health care company to do all we can to address this urgent unmet medical need."
The vaccine regimen combines a Janssen vaccine with a vaccine from Bavarian Nordic, a Denmark-based biotechnology company. In early clinical studies, the vaccine has shown promising results and is planned to be tested in healthy volunteers in Europe, the United States and Africa starting in early January.
"Our goal to produce more than a million vaccines in the next few months is within reach," Johnson & Johnson Chief Scientific Officer and Worldwide Chairman of Pharmaceuticals Paul Stoffels said. "Ebola is a significant and growing threat to the people of West Africa and it has the potential to impact people around the world. We are committed to bringing our science, technology, innovation and resources to help prevent and treat this deadly disease."